Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
- 1 October 2010
- journal article
- research article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 14 (46) , 1-130
- https://doi.org/10.3310/hta14460-01
Abstract
Health Technology Assessment Volume: 14, Issue: 46 Article 1, Published in October 2010Keywords
Funding Information
- Health Technology Assessment Programme (09/94/01)
This publication has 18 references indexed in Scilit:
- Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trialVaccine, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Expediting clinical trials in a pandemicBMJ, 2009
- Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenzaVaccine, 2009
- Reproducibility of Serologic Assays for Influenza Virus A (H5N1)Emerging Infectious Diseases, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Vaccines for preventing influenza in healthy childrenPublished by Wiley ,2008
- A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccinesVaccine, 2005